Further Information
Protein SET, HLA-DR-associated protein II, Inhibitor of granzyme A-activated DNase, IGAAD, PHAPII, Phosphatase 2A inhibitor I2PP2A, I-2PP2A, Template-activating factor I, TAF-I, SET
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:10~50
Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone binding. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T-lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins; however, isoform 2 specific activity is higher.
- Kim, D.W., et al. Biochem. Biophys. Res. Commun. 400(3):419-425(2010)
- Chao, A., et al. Cancer Lett. 291(1):99-107(2010)
- Jugessur, A., et al. PLoS ONE(7), E11493 (2010) :
- Samanta, A.K., et al. Oncogene 28(14):1669-1681(2009)
Supplied in PBS with 0.09% (W/V) sodium azide.
batch dependent
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Predicted species reactivity based on immunogen sequence: Drosophila, Mouse, Rat
This SET antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 47-75 amino acids from the N-terminal region of human SET.
6418
Protein SET
SET
Homo sapiens
Liquid
PREDICTED MOLECULAR WEIGHT:
33 kDa
Q01105
46397790
This antibody is purified through a protein A column, followed by peptide affinity purification.
Cancer,Cell Cycle,Immunology,Neuroscience,Signal Transduction
Q01105
Optimal dilutions for each application to be determined by the researcher.